Xiaoyong Huang

机构：Sunnybrook Health Science Centre, Ministry of Education of the People's Republic of China, Army Medical University, Sun Yat-sen University, Fudan University, Ministry of Education, Shanghai Institute of Organic Chemistry, Zhongshan Hospital, The First Affiliated Hospital, Sun Yat-sen University, Southwest Hospital, Ministry of Education, Sunnybrook Research Institute, Xi'an Jiaotong University · ORCID：0000-0002-5946-4737

发表论文 81 篇 · 总被引 2727 次 · h-index 28

代表论文

• Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study (2023 · Signal Transduction and Targeted Therapy · 被引 156)
• Macro CD5L+ deteriorates CD8+T cells exhaustion and impairs combination of Gemcitabine-Oxaliplatin-Lenvatinib-anti-PD1 therapy in intrahepatic cholangiocarcinoma (2024 · Nature Communications · 被引 47)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• Oncogenic miR-93-5p/Gal-9 axis drives CD8 (+) T-cell inactivation and is a therapeutic target for hepatocellular carcinoma immunotherapy (2023 · Cancer Letters · 被引 22)
• Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study (2025 · The Lancet Oncology · 被引 20)
• Targeting S100A9 Prevents β-Adrenergic Activation–Induced Cardiac Injury (2024 · Inflammation · 被引 13)